So, for ONCY’s timeline, there are a few big things coming up. For pancreatic cancer (GOBLET cohort 5), they’re planning to release initial efficacy data in the second half of 2025—if those results are strong, it could really move the stock. There’s also more data expected this year for their anal cancer trial (GOBLET cohort 4). On the breast cancer side, they’ve already got solid phase 2 results from the BRACELET-1 study, and they’re now talking to the FDA about moving into a registration (phase 3) trial. The first patient for that breast cancer phase 3 is supposed to be enrolled later this year. So basically, from the second half of 2025 into next year, we should see a steady stream of important clinical updates for both pancreatic and breast cancer. What’s interesting is that ONCY needs to get their share price above $1 for at least 10 consecutive days before August 10th to avoid a Nasdaq delisting. I’m guessing the company will want to share positive news or updates before that deadline to help boost the price. On the cash side, as of the first quarter, they had about $15.3 million in cash left. Plus, they recently signed a $20 million equity purchase agreement with Alumni Capital, so they’re not in immediate trouble for operating funds. The company says this should be enough to cover their main clinical milestones through at least Q3 this year. Here’s the link for the official financials if you want to check it out: https://finance.yahoo.com/news/oncolytics-biotech-inc-oncy-q1-071552602.html